ORIGINAL ARTICLE

The Effect of Bisphosphonates’ Oncologic dose on the Static and Dynamic Bone Parameters of the Temporomandibular Joint’s Condyle (A Randomized Animal Controlled Trial)

Israa A Radwan1, Samah Mehanny2, Marwa MS Abbass3

1Lecturer, Oral Biology Department, Faculty of Dentistry, Cairo University, Egypt
2Professor, Oral Biology Department, Faculty of Dentistry, Cairo University, Egypt
3Associate Professor, Oral Biology Department, Faculty of Dentistry, Cairo University, Egypt

(Received: 13 August 2020 Accepted: 29 September 2020)

ABSTRACT: The present study was conducted to assess the effect of oncologic dose of bisphosphonate on the condylar temporomandibular joint’s (TMJ’s) static and dynamic bone parameters. Forty adult male albino rats were utilized in the study. Animals were randomly assigned into four groups, each included ten rats that were intraperitoneally injected with saline (control groups I and II), or 0.2 mg.kg⁻¹ Zoledronic acid (experimental groups I and II). The rats were sacrificed at the end of 6 weeks (groups I) and 12 weeks (groups II). The right side TMJs condyles were used in histological and histomorphometric analysis while the left side condyles were utilized for assessing dynamic bone parameters. Bone volume/ Tissue volume (BV/TV) and trabecular thickness (Tb.Th) were significantly increased in ZOL group II as compared to control and Zoledronic acid (ZOL) group I (p<0.001) while trabecular separation (Tb.Sp) was markedly increased in ZOL group I as compared to both control and ZOL group II (p=0.001 and 0.012, respectively). The ZOL group II showed a significant increase in mineral apposition rate as compared to the ZOL group I (p<0.001). Our results demonstrated that oncologic dose of Zoledronic could have a catabolic effect on TMJ’s condyles after six weeks which is reversed after 12 weeks as evidenced by enhanced endochondral and intramembranous ossification.

INTRODUCTION

The innumerable functions of bone can be jeopardized by number of disorders that affect the structural and functional integrity of bone. The ability of the skeletal system to provide its supportive, protective, ambulatory functions as well as its function as a reservoir for mineral and growth factor storage and its blood cell formation functions can be greatly hindered by number of systematic diseases [1]. Diseases which may affect the bone can be broadly classified into metabolic bone diseases as Paget’s disease, hyperparathyroidism, hyperthyroidism, hypothyroidism, hypophosphatasia, and acromegaly. Genetic abnormalities as cherubism, osteopetrosis, osteogenesis imperfecta, and cleidocranial dysplasia. Developmental disorders as fibrous dysplasia, dystrophic bone disease as osteoporosis, inflammatory bone diseases as osteomyelitis, nutritional deficiency disorders as rickets, osteomalacia and scurvy as well as malignant lesions of the bone as osteosarcoma [2].

*Corresponding author: marwa.magdy@dentistry.cu.edu.eg (M. MS. Abbass)
DOI: 10.22034/jchr.2020.1906596.1165
Several options are available for the management of bone diseases among which are anti-resorptive medications such as bisphosphonates (BPs) [3, 4], anabolic agents, and combination therapy [5, 6]. BPs are the most used anti-resorptive drugs for the treatment of osteoporosis. Their chemical structure contains two phosphate groups with a core of phosphate-carbon-phosphate atoms (P–C–P bond) and two R side-chains [7, 8]. BPs, owing to their high affinity to hydroxyl apatite, can attach to the hydroxyl apatite at sites of active bone resorption, to be slowly released during subsequent bone remodeling. This can account for the slow elimination and consequently extended inter dosage durations of BPs [9–11]. BPs’ family includes non-nitrogen bisphosphonates and nitrogen BPs (N-BPs) which contain N group in the R side chain. N-BPs include alendronate (ALN), ibandronate, risedronate and zoledronate. N-BPs are more commonly used for osteoporosis treatment [12,13].

Zoledronic acid (ZOL) is a third generation N-BPs, with a great affinity for bone surface [14–16]. It is considered as one of the most potent BPs, owing to its strong ability to inhibit osteoclast function [17,18]. ZOL is usually prescribed as a single yearly dose of 5mg via intravenous injection [19]. Authors agree that patients are more likely to comply with yearly dosage of ZOL than with the frequent dosages of oral BPs [20, 21]. ZOL is successfully used for the management of postmenopausal osteoporosis [20–28], osteoporosis in men [29], and glucocorticoids induced osteoporosis [30]. Furthermore, ZOL can be administered as an adjunctive to anti-tumour therapy. The conventional oncologic dose of ZOL is 4mg administered intravenously every 3–4 weeks [31, 32]. Oncologic dose of ZOL can successfully control hypercalcemia and skeletal complications associated with bone metastases secondary to malignant tumours as multiple myeloma or malignancies of breast or prostate [33]. ZOL also has anti-angiogenic properties in vivo [34] and can help alleviate pain associated with bone metastasis [35, 36] which can further endorse its use alongside anti-tumour drugs.

ZOL is generally considered as a safe drug when used in low doses for osteoporosis treatment [37]. However, the administration of high or oncological dosages of ZOL can carry the risk of inducing BPs related osteonecrosis of the jaw [38]. BPs related osteonecrosis of the jaw can be defined as an exposed bone area in the maxillofacial region, with no prior radio-therapy history, that does not resolve within eight weeks in a patient on BPs treatment [39]. BPs related osteonecrosis of the jaw is linked to the suppressive effect of BPs on bone remodelling. Defective osteoclast function and inadequate bone repairing mechanism can result in bone necrosis [40].

The current study was conducted to assess the effect of oncologic dose of zoledronic acid on static and dynamic bone parameters of TMJ condyles in rats.

**MATERIALS AND METHODS**

**Experimental Procedures**

Forty adult male albino rats with an average weight of about 200-250 gm were used in this study. All the experimental procedures were conducted in the animal house, Faculty of Medicine, Cairo University, Egypt, according to the recommendations of the Institutional Animal Care and Use Committee (IACUC), Cairo University. Animals were housed individually in wire mesh cages. They were fed a standard pelleted diet and tap water ad-libitum. Temperature and humidity conditions were controlled during the experimental period.

The animals were assigned randomly into control groups (n=20) sacrificed either after 6 weeks (n=10) or 12 weeks (n=10) (control group I and control group II, respectively) and ZOL groups (n=20) sacrificed either after 6 weeks (n=10) or 12 weeks (n=10) (ZOL group I and ZOL group II, respectively). The results of both intervals of the control group were averaged and used as a single value for each sample.

ZOL (Zometa®, Novartis Pharma AG, Basel, Switzerland) was administered as weekly intraperitoneal injection of 0.2 mg.kg⁻¹ body weight [41]. The solution was prepared by dissolving 4 mg ZOL powder in 100 ml sterile saline, each rat received 0.04 mg/ml. The control group rats received weekly intraperitoneal injection of 1 ml of saline. For determining the dynamic bone parameters, bone labelling was performed with 0.5 ml intravenous injection of oxytetracycline for two days consecutively, one week prior to the experiment and one week before sacrifice the same protocol used for labelling by calcin [42].
Rats were sacrificed with ketamine overdose either after 6 or 12 weeks from the beginning of the experiment. The heads were sagittally dissected, fixed in 10% neutral formalin for 48 h. Both right and left TMJ were used, the right side TMJs condyles were used in histological and histomorphometric analysis while the left side condyles were utilized for assessing dynamic bone parameters.

**Light microscopic examination**

The right side TMJs condyles from each experimental group were washed and soaked in 10% ethylene diamine tetra-acetic acid (EDTA) for 4-5 weeks for decalcification. The specimens were dehydrated in ascending grades of alcohol following decalcification, then cleared in xylol and embedded in paraffin blocks. Sections of 4-5µ thickness were mounted on ordinary glass slides and stained by Hematoxylin and Eosin (H&E) for routine histological evaluation according to the conventional method.

**Fluorescence microscopic examination for dynamic bone parameters**

After fixation, the left side condyles were washed, dehydrated, and ground sections were prepared. The specimens were grinded to 0.1 mm (100 µm) thickness. After that, specimens were cleaned, dried, and mounted on slides to be examined with fluorescence microscope. Fluorescent microscope was used to identify the fluorescent labelled mineralization front [43].

**Histomorphometric analysis for static and dynamic bone parameters**

In the hematoxylin and eosin stained sections, Fiji image J (image analysis software) [44] with trainable Weka segmentation [45] and bone J [46] plugins, were used to analyze static and dynamic bone parameters. Image analysis was performed on images acquired with X10 magnification. Ten fields were measured from each sample and the mean values were calculated. Bone volume (BV) to tissue volume (TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), eroded surface to bone surface (ES/BS), and osteoblast surface to bone surface (OB/BS) were directly measured [43,47,48], while trabecular number (Tb.N) was measured indirectly using the following equation [49]:

\[
Tb. N = \frac{BV}{TV} \times \frac{TV}{Tb. Th}
\]

Mineral appositional rate (MAR) which is the distance between the edges of two fluorescent labels divided by the time between the labels [43], was measured in the images acquired using a fluorescent microscope.

**Statistical analysis**

Values were presented as mean and standard deviation (SD). Kolmogorov-Smirnov test of normality was used to explore data normality. The results of the Kolmogorov-Smirnov test indicated that data were normally distributed. One-way analysis of variance (ANOVA) test was used to assess significance between groups, this was followed by Tukey's post hoc test when ANOVA yielded a significant difference. The significance level was set at \(p < 0.05\). Statistical analysis was performed with SPSS 18.0 (Statistical Package for Scientific Studies, SPSS, Inc., Chicago, IL, USA) for Windows.

**RESULTS**

**Light microscopic examination**

**Control group**

The head of the rat’s TMJ condyle consisted of spongy bone with radiating trabeculae to the cortex. The bony trabeculae appeared as interconnecting plates lined by osteoblasts along their borders and with entrapped osteocytes (Figure A). A layer of hyaline cartilage could be distinguished with its characteristic oval shaped chondrocytes. The head was covered with a relatively thick layer of fibro-cartilaginous tissue. Regularly arranged fibroblasts oriented parallel to each other and to the joint cavity could be observed together with many dispersed chondrocytes (Figure 1A, B). The marrow spaces were filled with fibro-cellular tissue and were lined with osteoblasts (Figure C).
Figure 1. A photomicrograph of the condylar TMJ of control group showing: (A) Mandibular condyle composed of interconnected plates of spongy bone with its articulating surface covered by a thick layer of fibrocartilagenous tissue (bracket). (H&E staining. Scale bar represent 73μm). (B) A relatively thick layer of fibrocartilagenous tissue composed of fibrous layer (F), fibrocartilagenous layer (FC) and underlined by a layer of hyaline cartilage (C). (H&E staining. Scale bar represent 13μm). (C) Spongy bone with interconnecting bone trabeculae lined by osteoblasts (black arrow), enclosing marrow spaces (m), resting lines (yellow arrows) and osteocytes in their lacunae. (H&E staining. Scale bar represent 13μm).

**ZOL group I (6 weeks)**

The head of the condyle revealed marked thickening of the fibrous layer while thinning of the cartilaginous layer (Figure 1A). At the thin layer of hyaline cartilage, the chondrocytes displayed pleomorphism. In the deeper layers, they appeared spherical or ovoid and in the superficial layers; flattened or discoid. Some chondrocytic lacunae were completely empty; others were filled with amorphous material. In some lacunae, bone-like material could be detected either partially or entirely filling them (Figure 1A, B).

The subchondral bone revealed widened marrow spaces enclosing vascular-cellular elements (Figure 1A, C). Thin branching trabeculae with few entrapped osteocytes that appeared dispersed in widened lacunae; in some areas, the osteocytes lacunae completely disappeared (Figure 1). The architecture of the bone trabeculae exhibited abnormality regarding the presence of cracking and an enormous number of irregularly oriented reversal lines (Figure 1A, B). The bone trabeculae lost their regular osteoblastic lining except in focal dispersed areas, where the osteoblasts could be seen partially outlining their boundaries (Figure 1). Bone sequestration could be seen with small, detached pieces of necrotic bone (Figure 1A, C).
Figure 1. A photomicrograph of TMJ’s condyle of ZOL group I (6 weeks) showing:(A) Atypical histology of the condylar head with extremely widened and interconnected marrow spaces (m), enclosing cellular elements with apparent loss of the osteoblastic lining (black arrows), cracks (yellow arrow), areas of necrotic (N) and punched or teared bone (red arrows). (H&E staining. Scale bar represent 73μm) (B) Apparent thickening of the fibrous lining (F) of the articular surface with decrease of the fibrocartilaginous (FC) and cartilaginous layers (C), multiple cracks (yellow arrows). (H&E staining. Scale bar represent 13μm) (C) Widened marrow space (m) occupied with cellular and vascular tissue enclosing sequestrated bone (Sq); in some bone trabecula, few entrapped population of degenerated osteocytes (blue arrows); in other areas, complete loss of osteoblasts outlining bone boundaries (black arrows) as well as detached osteoclast (red arrow). (H&E staining. Scale bar represent 13μm) (D) Necrotic bone (N) and cracks (yellow arrows). (H&E staining. Scale bar represent 13μm)

**ZOL group II (12 weeks)**

After 12 weeks from ZOL administration, the fibrous layer and the fibrocartilaginous layer displayed marked thickening with a relative increase in the thickness of the cartilaginous layer (Figure A, B). The cartilage cells also displayed pleomorphism and appeared spherical or ovoid (Figure A, C). The cartilage cells undergo endochondral ossification (Figure A, C).

The head of the condyle revealed increase in the trabecular thickness with narrowing of the marrow spaces enclosing highly cellular elements (Figure A, C). The thick bone trabeculae revealed multiple randomly arranged large sized osteocytes. The bone trabeculae denoted a high bone formation rate in the form of multiple resting lines as well as unduly calcified bone matrix that took intensely the haematoxylin stain with islands of woven bone (Figure A, D). The marrow spaces were bounded with resting osteoblasts while many active osteoblasts appeared to be newly differentiated within the bone marrow and begin to lay bone matrix (Figure C).
Histomorphometric results

The histomorphometric results of static and dynamic bone parameters are presented as means ± standard deviation (± SD) in Tables 1, 2 and Figure 3.

Static bone parameters

Bone volume/ Tissue volume (BV/TV) and Trabecular thickness (Tb.Th)

A significant increase in mean BV/TV and Tb.Th was detected at the ZOL group II (12 weeks) as compared to both control and ZOL group I (p<0.001). On the contrary, a non-statistically significant difference was detected between the control and the ZOL group I (6 weeks) in the previously mentioned parameters (p=0.62 and p=0.81, respectively).

Trabecular separation (Tb.Sp)

A significant increase in mean Tb.Sp was recorded at the ZOL group I (6 weeks) as compared to both the control and the ZOL group II (12 weeks) (p=0.001 and 0.012, respectively). A non-statistically significant difference was detected between the control group and ZOL group II (12 weeks) (p= 0.677).

Trabecular number (Tb.N)

The highest mean trabecular number was evident in the control group with a statistically significant difference with the ZOL groups I and II (p=0.034 and p=0.003, respectively). While no statistically significant difference was detected between the ZOL groups I and II (p= 0.662).
Osteoblasts surface to bone surface (Ob/BS) and eroded surface to bone surface (ES/BS)

Control group showed the highest mean osteoblasts surface to bone surface followed by the ZOL group II (12 weeks) (0.6050 and 0.5556, respectively) with a statistically significant difference between the groups (p<0.001). No significant difference was detected between the control group and the ZOL group II (p=0.235).

On the contrary, the ZOL group I (6 weeks) revealed the highest mean eroded surface to bone surface with an overall statistically significant differences between all the groups (p<0.001).

Table 1. The static bone parameters.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean</th>
<th>Std. Dev</th>
<th>Std. Error</th>
<th>95% Confidence Interval for Mean</th>
<th>F</th>
<th>Sig.</th>
</tr>
</thead>
<tbody>
<tr>
<td>BV/TV</td>
<td>12 weeks</td>
<td>0.8171</td>
<td>0.1184</td>
<td>0.0265</td>
<td>24.89</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td></td>
<td>6 weeks</td>
<td>0.5424</td>
<td>0.1641</td>
<td>0.0367</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>0.5818</td>
<td>0.1107</td>
<td>0.0247</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trabecular thickness (Tb.Th)</td>
<td>12 weeks</td>
<td>70.7</td>
<td>54.4</td>
<td>12.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 weeks</td>
<td>31.45</td>
<td>10.34</td>
<td>2.31</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>25.15</td>
<td>5.27</td>
<td>1.18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trabecular separation (Tb.Sp)</td>
<td>12 weeks</td>
<td>25.51</td>
<td>17.59</td>
<td>3.93</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 weeks</td>
<td>49.82</td>
<td>40.92</td>
<td>9.15</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>18.57</td>
<td>6.21</td>
<td>1.39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tb.N</td>
<td>12 weeks</td>
<td>16.44</td>
<td>8.27</td>
<td>1.85</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 weeks</td>
<td>18.32</td>
<td>6.39</td>
<td>1.43</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>23.87</td>
<td>5.56</td>
<td>1.24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ob/BS</td>
<td>12 weeks</td>
<td>0.5556</td>
<td>0.0720</td>
<td>0.0161</td>
<td>50.84</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td></td>
<td>6 weeks</td>
<td>0.3217</td>
<td>0.0836</td>
<td>0.0187</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>0.6050</td>
<td>0.1218</td>
<td>0.0272</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ES/BS</td>
<td>12 weeks</td>
<td>0.1517</td>
<td>0.0545</td>
<td>0.0122</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6 weeks</td>
<td>0.1951</td>
<td>0.0458</td>
<td>0.0102</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>0.0622</td>
<td>0.0154</td>
<td>0.00346</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Dynamic bone parameters

Mineral apposition rate (MAR) (um/day):

The ZOL group II showed a statistically significant decrease in mineral apposition rate as compared to the control and the ZOL group I (p<0.001). (Figure 2, Table 2, Figure 3)
Figure 2. A tetracycline-fluorescence labelling of TMJ condyles showing the mineral apposition rate (MAR) in control group (A), ZOL group I (6 weeks) (B), ZOL group II (12 weeks) (C). (Tetracycline, Scale bars represent 27µm)

Table 2. Dynamic bone parameters

<table>
<thead>
<tr>
<th></th>
<th>Mean</th>
<th>Std. Dev</th>
<th>Std. Error</th>
<th>95% Confidence Interval for Mean</th>
<th>F</th>
<th>Significant</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 weeks</td>
<td>2.7917</td>
<td>0.2501</td>
<td>0.0559</td>
<td>(2.2889, 3.2946)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 weeks</td>
<td>4.933</td>
<td>1.320</td>
<td>0.295</td>
<td>(4.430, 5.436)</td>
<td>50.82</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Control</td>
<td>5.752</td>
<td>1.407</td>
<td>0.315</td>
<td>(5.250, 6.255)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DISCUSSION

ZOL is a third generation N-BPs used as an adjunctive treatment in cancer therapy to reduce skeletal effect of bone metastases [50], cancer related hypercalcemia [33], and can also help alleviate pain associated with bone metastasis [35,36]. Through the current study, ZOL was administered in oncologic dose at two intervals 6 weeks and 12 weeks to investigate its effect on mandibular condylar bone static and dynamic parameters.

In the present study, following 6 weeks of ZOL treatment, the subchondral TMJ bone revealed widened marrow spaces with thin branched trabeculae that entrapped few osteocytes in wide lacunae. Osteocytes completely disappeared in some areas, bone sequestration with small, detached pieces of necrotic bone were observed in some areas denoting BPs related osteonecrosis of the jaw. These findings coincide with
those reported by Silva et al., [51], who noticed Bps-related osteonecrosis of the jaw and increase in radioluent areas in Wister rats after treatment with 0.2 and 1.0 mg.kg\(^{-1}\) ZOL for four weeks. However, bone degeneration was relatively reversed in our study in the ZOL group II (12 weeks) due to new endochondral and membranous bone formation. According to the histomorphometric results of the current study, a net catabolic effect has been recorded following treatment by ZOL for six weeks. This is indicated by the significant increase in Tb.Sp. and eroded surface to bone surface in this group as compared to the control or ZOL (12 weeks) group which could be attributed to Bps related osteonecrosis of the jaw. The exact mechanism by which ZOL can induce osteonecrosis of the jaw is not yet clear. The decreased bone turnover due to Bps inhibitory action on bone resorption secondary to Bps effect on osteoclasts [52] has been suggested as a primary mechanism involved in the development of Bps related osteonecrosis of the jaws [51]. Moreover, inflammation has also been implicated in pathogenesis of Bps related osteonecrosis of the jaws. Rats treated with 0.2 and 1.0 mg.kg\(^{-1}\) doses of ZOL showed an increase in lymphocytes, neutrophils, and monocytes in post-extraction bone site. This lymphocytosis occurs secondary to the release of pro-inflammatory cytokines (interferon-\(\gamma\), interleukins (IL) 1\(\alpha\), 2, 6, 10, tumor necrosis factor alpha (TNF\(\alpha\)), C-X-C Motif Chemokine Ligand 1 (CXCL1) and monocyte chemoattractant protein) [51]. Additionally, N-Bps were found to have a direct inhibitory action on bone-forming cells viability and alkaline phosphatase activity in vitro, low doses of both ALN and ZOL rapidly increased the release TNF\(\alpha\) and IL-1\(\beta\), as well as dickkopf WNT signalling pathway inhibitor 1 (DKK 1) and sclerostin, both inhibitors of osteoblastogenesis. Moreover, ALN and 10\(^{-7}\) M of ZOL decreased the expression of type I collagen and osteopontin, while both drugs slightly stimulated secreted protein, acidic and rich in cysteine (SPARC) production [53]. Osteopontin is a non-collagenous bone matrix protein essential for regulation of bone remodeling. It is implicated in inhibition of hydroxypatite growth and bone mineralization [54]. The latter findings support and explain the recorded absence of osteoblastic linings as well the widened marrow cavities in ZOL group I (6 weeks) in the present study. Nevertheless, these mediators level is time and dose dependent, as their levels decreased from day 3 to day 7 [53]. Unlike results reported in the current study, ZOL administration to mice at weekly dose of 0.5 mg.kg\(^{-1}\) weekly for 3 weeks was associated with significant increase in bone mineral density and bone mineral content, significant increase in BV/TV, Tb.N, and decreased Tb.Sp, as well as significant decrease in serum markers of osteoblast and osteoclasts reflecting the ability of ZOL to suppress bone remodeling compared with controls [55]. This contradiction can be attributed to different dosage scheme used in our study. A significant increase in ES/BS while a significant decrease in the Ob/BS in the ZOL group I (6 weeks) as compared to both the control and the ZOL group II (12 weeks) have been recorded through the ongoing study. This denoted a relative transient increase in osteoclastic action and in upregulation of Receptor activator of nuclear factor kappa-B ligand (RANKL)/osteoprotegerin (OPG) axis which might be referred to the initial increase in the inflammatory mediators during this time lap. Through the current study, the administration of ZOL for 12 weeks was associated with a significant increase in static bone parameters BV/TV, Tb.Th, Ob/BS and a significant decrease in ES/BS and MAR as compared to the control and ZOL group I (6 weeks). These findings indicate that the increase in the bone volume observed in the 12 weeks group the current study is attributed to ZOL bone resorption suppression as a result of osteoclasts inhibition, which subsequently surpass the osteoblasts activation and cause new bone formation. Preclinical studies have demonstrated the efficacy of ZOL as an adjunctive treatment for bone metastasis. Oncological dose of ZOL induced osteosclerosis and was associated with improved bone histomorphometric parameters and disrupted osteoclasts function in rats with lymph node and lung cell tumor bone metastasis [56]. ZOL also effectively reduced bone resorption and increased bone density in osteosarcoma rat model [57]. Furthermore, ZOL significantly increased bone volume, trabecular number, and significantly reduced osteoclasts number in rats injected with breast cancer cells [58]. The effect of oncologic dose of ZOL on bone architecture
was previously studied by Camacho-Alonso et al. Rats receiving weekly dose of 0.2 mg.kg$^{-1}$ ZOL for 1, 2 or 3 weeks displayed significantly higher fracture resistance in mandibular condyle and femur head. The mandibular condyle displayed a higher calcium and phosphorous content as compared to the control group [59]. Furthermore, administration of ZOL oncologic dose for 3 and 6 months were associated with significant reduction in dogs’ mandible MAR and bone remodelling as compared to control [60] which coincide with findings reported in the current study as despite the significant increase in the static bone parameter in the ZOL group II in our study, the newly formed bone wasn’t qualitatively mineralized as revealed in the haematoxylin stained bone matrix which indicated less mineral content. Similar improvement in static bone parameters while reduction in MAR results were attained upon administration of ZOL to OVX monkeys. The decreased MAR rate at ZOL group II could be attributed to the difference structure-related remodelling rate between the cancellous bone and cortical bone [61]. Interestingly, ZOL administered to rats at a dose of 0.1 mg.kg$^{-1}$ for 2 months significantly increased the volume of fibrous cartilage of the condyle [62].

Several clinical studies further endorsed the efficacy of ZOL as an adjunctive treatment for bone metastases. ZOL was associated with increase in bone mineral density, trabecular bone score and reduced skeletal complications in women with bone loss induced by breast cancer treatment [63–65], in addition to reduced complications related to bone metastases secondary to prostate cancer in men [66, 67] and secondary to tumours other than breast or prostate cancer [68].

The current reported findings reflect the mode of action of ZOL upon both short and long term exposure. ZOL is associated with a primary increase in the level of inflammatory mediators [53] which is associated with increased RANK expression and active bone resorption associated with a direct inhibitory action on bone-forming cells [53]. ZOL administration is also associated with reduction in bone remodelling by disrupting osteoclasts morphology [69] in addition to exerting an inhibitory effect on osteoclast cell function [70] and recruitment via reducing RANK expression [71] as well as inducing osteoclasts apoptosis [72].

It has been authorized that N-Bps including ZOL can interfere with osteoclasts differentiation and survival indirectly through diminishing the instructive influence of osteoblast on osteoclastic cells differentiation [73,74]. N-Bps can down regulate expression of RANKL and upregulate expression of OPG by osteoblast [75,76]. RANKL and OPG are key regulators of osteoclast differentiation [77] and are essential for the modulation of the bone resorption process [78]. RANKL and OPG are cytokines within the TNF family, produced mainly by osteoblast cells for the regulation of osteoclastogenesis and bone resorption. Upon binding of RANK-L to its receptor RANK expressed on surface of osteoclast precursor cells, it stimulates osteoclastogenesis, osteoclast survival and bone resorption. OPG on the other hand is a receptor antagonist that prevents RANK to RANK-L interaction to inhibit osteoclast differentiation, function, promote their apoptosis and prevents bone resorption [79]. This can account for the significant reduced ES/BS associated with the significant increase in Ob/BS in ZOL group II (12 weeks) as compared with ZOL group I (6 weeks) observed in the current study.

The influence of N-Bps on bone homeostasis and bone remodelling doesn’t only rely on osteoclast inhibition, but it can also affect osteoblast homeostasis [73,80]. The effect of ZOL on osteoblasts seems to be dose and time dependant. Therapeutic doses for osteoporosis management (10$^{-7}$ M or less) were associated with increased osteoblasts proliferation [81], while higher doses were associated with suppression of osteoblasts proliferation, increased apoptosis and cytotoxicity [55,81–83], decreased cell viability and migration [83] in vitro. In addition to inhibition of osteoblasts proliferation, differentiation and function [84]. These findings can explain the initial reduced Ob/BS in the current study after administration ZOL for six weeks.

The active endochondral ossification, woven bone formation and active osteoblastic lining of the bone marrow cavities reported in the histological sections of the condyles of the rats administrated ZOL for 12 weeks in the present study are supported and explained by the results of the study carried out by Hao el. 2015. They reported woven bone formation in 0.1 mg.kg$^{-1}$ ZOL-treated Sprague-Dawley rats at early stage of
osteoporotic fracture healing while the cartilage and fibrocartilage persisted in the majority of the control animals. ZOL enhanced callus growth and mineralization, instead of blocking endochondral bone formation and the subsequent transformation of fibrocartilage callus into woven bone [85]. ZOL could enhance the proliferation and osteogenic differentiation of MSCs [81,86], and increase osteoblast proliferation, differentiation, and mineralization [87] or even would not inhibit mineralization [88,89]. Moreover, it has been deduced that ZOL could protect cartilage and subchondral bone by lessening the degree of overlying cartilage degeneration and reducing bone resorption in osteoarthritis models [90,91] which coincide with findings observed in ZOL group II (12 weeks ) in the current study.

In conclusion, our study suggests that oncologic doses of ZOL on long term could enhance endochondral and intramembranous ossification of TMJ condyles. This study also provides evidence that the deleterious effect of bisphosphonates in inducing jaw necrosis could be reversed into a beneficial role by enhancing new woven bone formation through endochondral ossification which should help in clinical treatment of subchondral fractures. Further studies with successive sacrificing dates starting from the first week of ZOL administration need to be held to clarify the exact correlation between inflammatory mediators’ level with bone early and late osteogenic markers as well as RANK expression.

**CONFLICT OF INTERESTS**

The authors declare that they have no conflicts of interest.

**REFERENCES**

14. Nancollas G.H., Tang R., Phipps R.J., Henneman Z.,
women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab. 99 (December), 4546–4554. https://doi.org/10.1210/jc.2014-1971.


57. Labrinidis A., Hay S., Liapis V., Findlay D.M.,


osteoclast precursors during osteoclastogenesis. Naunyn-
Schmied Arch Pharmacol. 383, 297–308. 
https://doi.org/10.1007/s00210-010-0596-4.
72. Kellinsalmi M, Mönkkönen H, Mönkkönen J, 
Leskelä H-V, Parikka V, Hämäläinen M, Lehenkari P, 
2005. In vitro comparison of clodronate, pamidronate 
and zoledronic acid effects on rat osteoclasts and human 
Toxicol. 97(6), 382–391. https://doi.org/10.1111/j.1742-
bisphosphonates in bone: preservation of osteoblast and 
https://doi.org/10.1016/j.bone.2010.08.008.
74. Nishikawa M, Akatsu T, Katayama Y, Yasutomo 
Bisphosphonates act on osteoclastic cells and inhibit 
osteoclast formation in mouse marrow cultures. Bone. 
18(1), 9–14.
75. Viercke V, Emoms G, Lauck V, Frosch K.H, 
Bisphosphonates pamidronate and zoledronic acid 
stimulate osteoprotegerin production by primary human 
osteoblasts. Biochem Biophys Res Commun. 291(3), 
76. Pan B, Farrugia A.N, To L.B, Findlay D.M, Green 
containing bisphosphonate, zoledronic acid, influences 
RANKL expression in human osteoblast-like cells by 
activating TNF-alpha converting enzyme (TACE). J 
Bone Miner Res. 19(1), 147–154. 
77. Nanci A, 2013. Ten Cate’s Oral Histology: 
development, structure and function, eighth ed; St 
Louis: El Sevier Mosby.
79. Tyrovola J.B, Spyropoulou M.N, Makou M, Perrea 
D, 2008. Root resorption and the OPG / RANKL / 
376.
80. Plotkin L.I, Lezcano V, Thostenson J, Weinstein 
R.S, Manolagas S.C, Bellido T, 2008. Connexin 43 is 
required for the anti-apoptotic effect of bisphosphonates 
on osteocytes and osteoblasts in vivo. J Bone Miner Res. 
23(11), 1712–1721. https://doi.org/10.1359/jbmr.080617.
81. Corrado A, Neve A, Marotti N, Gaudio A, 
metabolic effect of zoledronate on primary human 
osteoblastic cell cultures. Clin Exp Rheumatol. 28(6), 
873–879.
82. Huang X, Huang S, Guo F, Xu F, Cheng P, Ye Y, 
Dong Y, Xiang W, Chen A, 2016. Dose-dependent 
inhibitory effects of zoledronic acid on osteoblast 
83. Zafar S, Coates D.E, Cullinan M.P, Drummond 
B.K, Milne T, Seymour G.J, 2016. Effects of 
zoledronic acid and geranylgeraniol on the cellular 
behaviour and gene expression of primary human 
alveolar osteoblasts. Clin Oral Investig. 20(8), 2023– 
84. Patnirapong S, Singhathanadgit W, Chanruangvanit 
acid suppresses mineralization through direct 
cytotoxicity and osteoblast differentiation inhibition. J 
Dai K, 2015. Zoledronic Acid Suppresses Callus 
Remodeling but Enhances Callus Strength in an 
Osteoporotic Rat Model of Fracture Healing. Bone. 81, 
702–711.
Huang F, Zhao R.N, Chen Y.J, 2011. Ibandedronate 
promotes osteogenic differentiation of periodontal 
ligament stem cells by regulating the expression of 
micrornas. Biochem Biophys Res Commun. 404(1), 
127–132.
87. Greiner S, Kadow- Romacker A, Lübberstedt M, 
zoledronic acid incorporated in a poly (d, lacticide) 
implant coating on osteoblasts in vitro. J Biomed Mater 
S.H, 2008. Aminobisphosphonates cause osteoblast 
apoptosis and inhibit bone nodule formation in vitro. 
Calcif Tissue Int. 82(3), 191–201.
89. Reinholz G.G, Getz B, Pederson L, Sanders E.S, 
312
Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 60(21), 6001–6007.

